The Danish Competition Authority fines a pharmaceutical company for abuse of dominance by charging unfair prices (CD Pharma)

CD Pharma has abused its dominant position by increasing their price by 2,000 percent* On 31 January 2018, the Danish Competition Council (“DCC”) ruled in a case concerning CD Pharma’s (a pharmaceutical distributor) abuse of dominant position by charging unfair prices for the drug Syntocinon. Syntocinon contains oxytocin, which is an active substance given to pregnant women in connection with childbirth. From 28 April 2014 until 27 October 2014 CD Pharma increased the price on

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Danish Competition Authority, The Danish Competition Authority fines a pharmaceutical company for abuse of dominance by charging unfair prices (CD Pharma), 31 January 2018, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 86544

Visites 269

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues